🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million new cases each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured over nine in ten of cases of the STI. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The research included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have voiced positive views. Having a one-pill regimen like this is described as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the illness for people and to halt the transmission of untreatable gonorrhoea globally.